Smoldering Plasma Cell Myeloma Clinical Trial
Official title:
Phase II Trial of Isatuximab (SAR650984) With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
PRIMARY OBJECTIVE: - To determine the rate of response according to the International Myeloma Working Group Criteria. SECONDARY OBJECTIVES: - To determine progression free survival (PFS) at 2 years. - To determine overall survival (OS). - To determine duration of response (DOR). - To determine the clinical benefit rate (CBR). - To evaluate safety of single agent treatment in this population - To evaluate safety of single agent treatment in this population. - To evaluate the immunogenicity of isatuximab. OUTLINE: Patients on single agent cohort receive isatuximab intravenously (IV) over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Patients on Combination Cohort with Lenalidomide receive isatuximab as in single agent cohort plus Lenalidomide po 21/28 days during cycles 1-6 only. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6-12 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03937635 -
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
|
Phase 3 | |
Active, not recruiting |
NCT04370483 -
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
|
Early Phase 1 | |
Terminated |
NCT02353572 -
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05014646 -
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
|
Phase 2 | |
Active, not recruiting |
NCT05288062 -
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT05136807 -
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
|
||
Recruiting |
NCT05312255 -
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
|
N/A | |
Active, not recruiting |
NCT02603887 -
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
|
Early Phase 1 | |
Active, not recruiting |
NCT03631043 -
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
|
Early Phase 1 | |
Recruiting |
NCT02726750 -
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
|
||
Withdrawn |
NCT03952832 -
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04776395 -
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
|
Phase 2 | |
Completed |
NCT02492750 -
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
|
Phase 1 |